Body
New research presented at this year's Euroanaesthesia congress in Vienna, Austria (1-3 June) shows that mortality in patients who had undergone heart bypass surgery was over 4 times higher in individuals with a high body fat mass, while body mass index (BMI) by itself was not associated with an increase in mortality. The research was conducted by Dr Xavier Leroy of the Department of Anaesthesia and Resuscitation, CHU Lille, Lille, France and colleagues.
A team of Japanese scientists has used facial recognition technology to develop an automated system that can predict when patients in the intensive care unit (ICU) are at high risk of unsafe behaviour such as accidentally removing their breathing tube, with moderate (75%) accuracy.
Blood transfusion during liver cancer surgery linked with higher risk of cancer recurrence and death
Receiving a blood transfusion during curative surgery for the most common type of liver cancer (hepatocellular carcinoma) is associated with a much higher risk of cancer recurrence and dying prematurely, according to new research being presented at this year's Euroanaesthesia congress (the annual meeting of the European Society of Anaesthesiology) in Vienna, Austria (1-3 June).
People admitted to NHS hospitals with a cardiac arrest over the weekend do not face a higher risk of dying compared to those admitted during the week, according to new research presented today at the British Cardiovascular Society (BCS) Conference in Manchester.
The research led by Dr Rahul Potluri, founder of the ACALM study unit at Aston University, investigated 4,803 people going to hospital with a cardiac arrest.
After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care.
Chicago - Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.
Patients who underwent total knee replacement and used a smartphone app (PainCoach) at home after surgery consistently reduced opiate painkiller use and improved pain control, according to new research being presented at this year's Euroanaesthesia Congress (the annual meeting of the European Society of Anaesthesiology) in Vienna, Austria (1-3 June).
The more the study participants used the app, the more likely they were to lower pain scores and decrease their use of opioids.
ABSTRACT LBA1008
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients, the agent has not clearly improved progression-free survival (PFS) or overall survival (OS) for trial participants with locally advanced non-small cell lung cancer (NSCLC). These results are based on local center reported outcomes. Trial participants will continue to be followed for changes in their status.
University of Colorado Cancer Center led clinical trial data show that a predictive tool called COXEN may show which bladder cancer patients will respond to pre-surgical chemotherapy, a step towards allowing doctors to offer such chemotherapy to patients likely to respond, while moving more efficiently to other treatment options with patients unlikely to benefit. Results will be presented Monday, June 3 at 8:00am as oral abstract at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting (ASCO abstract #4506).
CHICAGO -- Preliminary results from a University of North Carolina Lineberger Comprehensive Cancer Center study found that just 15 percent of a group of men in North Carolina with early-stage prostate cancer who choose active surveillance instead of treatment followed the recommended monitoring guidelines.
New research presented at this year's Euroanaesthesia congress (the annual meeting of the European Society of Anaesthesiology) in Vienna, Austria (1-3 June) shows that commonly used anaesthetic drugs still work, even after exposure to the extreme environmental conditions of the Antarctic. The study was conducted by Professor Major Ricardo Navarro-Suay of Hospital Central de la Defensa "Gómez Ulla", Madrid, Spain (who serves in the Spanish Armed Forces) and colleagues.
Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.
Research published in the April print edition of the journal Life Science Alliance, shows that antidepressant drugs called FIASMAs, including desipramine, amitriptyline, and nortriptyline, halt the growth or kill four different intracellular bacterial pathogens in tissue cell culture and animal models.
June 1, 2019--More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of inhaling vapors, gas, dust or fumes at work, according to a joint American Thoracic Society and the European Respiratory Society statement published in the ATS's American Journal of Respiratory and Critical Care Medicine.
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK+ NSCLC). Since then, a range of next-generation ALK-inhibitors including ceritinib, alectinib, and brigatinib have earned FDA approval as second-line therapies after treatment with crizotinib. However, each of these next-generation ALK-inhibitors can also be used in the first-line setting, and an important question becomes which, if any, remain useful when given after another next-generation drug?
Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and these differences in trial designs can lead to irrelevant comparisons - like comparing athletes' running times without noting that one ran a kilometer while the other ran a mile.